Success RatesUnfortunately, not all women who ovulate during this treatment will become pregnant. The majority of pregnancies occur in the first three ovulatory treatment cycles. Very few pregnancies are achieved in patients who do not conceive in the first six ovulatory cycles. The cumulative pregnancy rates after several ovulatory cycles on clomiphene citrate are generally less than 50%. Related Links FOLLISTIM AQ (follitropin beta injection) is approved for women to help healthy ovaries to develop and release mature eggs. FOLLISTIM AQ is also for women participating in an assisted reproductive technology (ART) program to help the ovaries produce more mature eggs. FOLLISTIM AQ is also approved for men to help bring about the production and development of sperm. Important Safety Information About FOLLISTIM AQ: • Do not use FOLLISTIM AQ if you are allergic to recombinant human follicle-stimulating hormone (FSH) products; have a high level of FSH in your blood indicating that your ovaries (women only) or testes (men only) may be permanently damaged and do not work at all; have uncontrolled thyroid, pituitary or adrenal gland problems; are allergic to streptomycin or neomycin (types of antibiotics); have a tumor of the hypothalamus, pituitary gland, breast, uterus (women only) or ovary (women only), or testis (men only); are a women who is pregnant or think you may be pregnant; have heavy or irregular vaginal bleeding and the cause is not known; have ovarian cysts or enlarged ovaries not due to polycystic ovary syndrome (PCOS). • Be sure that you read, understand, and follow the "Patient Instructions for Use" that come with FOLLISTIM AQ. Use FOLLISTIM AQ exactly as your healthcare provider tells you to. Your healthcare provider will tell you how much FOLLISTIM AQ to use, how to inject it, and how often it should be injected. Do not inject FOLLISTIM AQ at home until your healthcare provider has taught you the right way. Do not mix FOLLISTIM AQ with any other medicines in the same vial or in the same syringe. Do not change your dose of FOLLISTIM AQ unless your healthcare provider tells you to. Call your healthcare provider immediately if you use too much FOLLISTIM AQ. If you miss or forget to take a dose, do not double your next dose. Ask your healthcare provider for instructions. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. Please see accompanying important patient information for Follistim AQ Vial. Please see accompanying important patient information for Follistim AQ Cartridge. PREGNYL is approved to induce ovulation and pregnancy in women who have problems with ovulation and who have been appropriately pretreated with human menopausal gonadotropins (medications containing follicle-stimulating hormone [FSH] and luteinizing hormone [LH]). PREGNYL will not help women whose ovaries do not work at all (primary ovarian failure). Important Safety Information About PREGNYL: • Do not use PREGNYL if you are allergic to human chorionic gonadotropin (HCG). • PREGNYL should be used in conjunction with human menopausal gonadotropins. • PREGNYL should only be prescribed by physicians experienced in infertility treatments. • Anaphylaxis has been reported with urinary-derived HCG products. • PREGNYL may cause ovarian hyperstimulation syndrome (OHSS), which is a serious medical problem that can happen when the ovaries are overstimulated. In rare cases, it has caused death. OHSS causes fluid to build up suddenly in the stomach and chest areas. OHSS may occur after treatment with PREGNYL. Call your healthcare professional right away if you get any of the following symptoms: severe pelvic pain (lower stomach area), nausea, vomiting, sudden weight gain, diarrhea, reduced urine output, or trouble breathing. • PREGNYL may also cause rupture of ovarian cysts resulting in internal bleeding (hemoperitoneum), multiple births, and artery blockage by a blood clot (arterial thromboembolism). • Other side effects with PREGNYL include headache, irritability, restlessness, depression, fatigue, edema, and pain at the site of injection. • Hypersensitivity reactions, both localized and systemic in nature, have been reported. • If you get any side effects that concern you, call your healthcare professional. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. Please see accompanying important Product Information and discuss it with your doctor. Ganirelix Acetate Injection is approved for the inhibition of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation. Important Safety Information About Ganirelix: • Do not use Ganirelix Acetate Injection if you are allergic to Ganirelix Acetate or any of its components, gonadotropin releasing hormone (GnRH) or any other GnRH analog (including GnRH agonists and antagonists), or if you are pregnant or think you might be pregnant. If you get any side effects that concern you, call your healthcare professional. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. Please see accompanying important patient information for Ganirelix Acetate Injection. |
|